Retension Pharmaceuticals (NASDAQ:RTSN) Now Covered by Leerink Partners

Leerink Partners initiated coverage on shares of Retension Pharmaceuticals (NASDAQ:RTSN) in a report published on Tuesday,Zacks reports. The brokerage issued a strong-buy rating on the stock.

RTSN has been the subject of several other reports. Oppenheimer started coverage on Retension Pharmaceuticals in a research note on Tuesday. They issued an “outperform” rating and a $50.00 target price for the company. Guggenheim started coverage on Retension Pharmaceuticals in a research report on Monday. They set a “buy” rating and a $55.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the company’s stock. According to MarketBeat, Retension Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $52.50.

Retension Pharmaceuticals Stock Performance

RTSN stock opened at $11.60 on Tuesday. Retension Pharmaceuticals has a fifty-two week low of $9.66 and a fifty-two week high of $18.64.

Insider Buying and Selling

In other Retension Pharmaceuticals news, CEO Eric Keller bought 20,800 shares of the stock in a transaction on Tuesday, October 13th. The stock was purchased at an average price of $12.00 per share, with a total value of $249,600.00. Following the acquisition, the chief executive officer owned 423,377 shares of the company’s stock, valued at approximately $5,080,524. The trade was a 5.17% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Franklin Berger bought 10,000 shares of the stock in a transaction on Tuesday, October 13th. The shares were acquired at an average cost of $12.00 per share, with a total value of $120,000.00. Following the acquisition, the director directly owned 10,000 shares in the company, valued at approximately $120,000. This trade represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing.

Retension Pharmaceuticals Company Profile

We are a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Our product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (“PDE-5”) inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. While first-generation PDE-5 inhibitors, such as Viagra (sildenafil), were originally studied in cardiovascular indications such as hypertension and angina, we believe they did not have adequate bioavailability and tissue penetration to impact the smooth muscle cells of the central vascular and cardiac tissues and thus failed to achieve clinically meaningful reductions in blood pressure.